The Psychedelics Newsletter, Issue 138

PSYCH Symposium: exploring psychedelic medicine

PSYCH Symposium: London 2023 brought together key stakeholders to explore the landscape of psychedelic medicine at the British Museum on Thursday, 6 July.

Featuring leading minds in psychedelic science and policy, alongside changemakers and patients, the event delved into the challenges and developments of the sector.

Panels, workshops and fireside chats explored areas of psychedelic healthcare from challenges in clinical development, trial designs and regulation, to the medicines’ applications in areas such as eating disorders, addiction and relationships.

READ MORE

ADVANCING PSYCHEDELIC HEALTHCARE IN EUROPE

Industry stakeholders, medical professionals and investors converged to promote psychedelic therapy.

READ MORE

NEUROIMAGING AND PSYCHEDELIC MEDICINE

It is unclear whether the quality of a patient’s psychedelic experience relates to the clinical effects.

READ MORE

BUSINESS AND INVESTMENT

• COMPASS projects 2027 timeline for?commercialisation of psilocybin therapy.?The company made the prognostication at Psych Symposium: London 2023.
• Funding psychedelic research in?Europe and North America.?Negev Capital aims to innovate mental healthcare by financing clinical trials.
• The?landscape of psychedelic healthcare.?The process of conducting psychedelic trials can be particularly complicated.
• Small Pharma provides?update on SPL028.?The company hopes to start Phase II trials of its DMT analogue in 2024.
• Cybin develops streamlined and scalable version of its?EMBARK training programme.?Cybin hopes to increase its ability to effectively qualify, train and certify facilitators.
• Filament Health to provide psilocybin for Canadian?government funded studies.?The clinical trials will study psilocybin therapy for alcohol use disorder and treatment-resistant depression.
• Bright Minds announces?date for share consolidation.?Post-consolidation shares are expected to begin trading on 14 July.
• Wesana Health announces?closure of SANA-013 sale.?Lucy Scientific Discovery purchased the compound for US$570,000 and 1,000,000 common shares.

SCIENCE AND RESEARCH

• Psychedelic?medicines and neuropathic pain.?The early evidence is promising, but without effective control groups is far from conclusive.
• Psilocybin-assisted therapy in the?treatment of anorexia nervosa.?The eating disorder has the highest mortality rate of any psychiatric condition.

Thank you to the incredible speakers who shared their knowledge and insights at PSYCH Symposium: London 2023.

Thank you for participating in discussions that will help shape the future of psychedelic medicine.

FULL LIST OF SPEAKERS

REGULATION AND LEGISLATION

• Scottish government calls on the UK to?enact decriminalisation measures.?It says more should be done to promote harm reduction.
• Berkeley City Council to vote on?psychedelic medicine reform.?Lawmakers are poised to enact decriminalisation measures.
• Lobbyists in Massachusetts file paperwork to put psychedelic medicine?reform on the 2024 ballot.?The filing hopes to expand treatment options.
• Australia’s regulation of psychedelic medicines?criticised by experts.?Psychiatrists argue the evidence for broad-scale implementation is insufficient.

ARTICLES OF INTEREST

• Research suggests 10% of UK suicides could?be work-related.?For every employee who dies by suicide, another 10 to 20 will attempt suicide.
• Canadian firefighters?focusing on mental health.?Climate change is bringing warmer and drier conditions, leading to longer wildfire seasons.